Frazier Life Sciences

Frazier Life Sciences is a life sciences investment firm that invests globally in private and publicly traded companies discovering, developing, and commercializing innovative biopharmaceuticals. It operates through two strategies: a venture arm focused on company creation and early-stage investment in private biopharmaceutical companies, and a public equity arm backing small- and mid-cap biopharmaceutical companies alongside private crossover opportunities.

Since 2015 the firm has created more than 25 companies, while portfolio companies have brought more than 75 FDA-approved drugs to market over the same period. Investment activity spans the therapeutic and technology areas of oncology, autoimmune disease, biologics, cell therapy and gene therapy, covering the arc from drug discovery through development and commercialization.

The firm applies scientific and clinical diligence to its investments and draws on industry operating experience, partnering with entrepreneurs and management teams and providing sustained support across company stages. Headquartered in Palo Alto, California, Frazier Life Sciences also has presence in San Diego, Boston and Seattle.